"[A] method for preventing and fighting the harmful
biological effects
of free radicals...namely...inflammation...[and] collagen
degradation" - U.S. Patent 4,698,360 inventor,
Dr. Jack Masquelier.
Healthier, Smoother Skin from
Within:
Flavay® Promotes Collagen Production,
Inhibits Elastin Degradation and Reduces Inflammation
Research has demonstrated that Flavay®
binds to collagen fibers and realigns them to a more youthful,
undamaged form.
Flavay® can have a dramatic, visible effect on your skin.
The nutrients in Flavay® can be considered as 'collagen
vitamins' because they partake in the biosynthesis of collagen
and prevent its destruction. Through synergistic action with
vitamin C, Flavay® strengthens and rebuilds the body’s
natural collagen proteins and has the remarkable ability to
reactivate damaged collagen and elastin. Research has demonstrated
that Flavay® binds to collagen fibers and realigns them
to a more youthful, undamaged form. (The same research also
established that common bioflavonoids are completely inactive
in this respect.) Flavay® improves the beneficial cross-linking
between the amino acids of the fibers that give skin its flexibility
and strength while preventing the undesirable cross-linking
between amino acids that ages skin like leather. Laboratory
tests have demonstrated Flavay’s®
ability to reduce degradation of elastin fibers by up to 70
percent.
Flavay® strengthens
and rebuilds the body’s collagen proteins and also
helps prevent the degradation of collagen and elastin,
thereby helping to enhance the elasticity of the skin
and offset visible signs of premature aging.
Flavay’s® ability to reactivate damaged collagen and elastin
has great implications for all of your body’s organs. Collagen
is required for the normal functioning of the joints, healthy
cartilage and bones, smooth gliding surfaces, synovial fluid,
normal joint spaces and normal soft tissues surrounding the
joints. Collagen is the building block of connective tissue,
veins, arteries, ligaments and tendons, and every tissue and
organ.
Flavay® Improves Circulation
to Skin Cells
Improved circulation is another reason that Flavay® is
an important part of optimally nourishing your skin. Over 50
years of scientific and clinical research establishes that Flavay®
actually strengthens collagen in vascular walls and capillaries
(the smallest vessels), by making the vessels stronger and more
elastic. As we age, the tiny capillaries begin to break down,
resulting in diminished blood flow. Fortifying these tiny blood
vessels will improve circulation throughout the body, including
the skin, delivering blood and nutrients to your skin. Improved
circulation results in well-nourished, healthy skin—which
is radiant and more youthful.
Inflammations and Edema (Swelling)
Flavay® has been licensed and sold in France for treating
edema and inflammations since 1950. Puffiness of the eyes and
an overall bloated look and feel are examples of edema. It involves
the leakage of blood serum into surrounding tissues and Flavay®
has shown that it can reduce this leakage by strengthening capillary
walls.
One of the very first benefits observed and studied by the
inventor of Flavay®, Dr. Jack Masquelier, in as early as
1947, was its anti-inflammatory effect. His and others' research
demonstrated that Flavay® inhibits the release and synthesis
of histamine (which produces accelerated blood flow, dilates
capillaries and increases their permeability, thereby leaking
plasma into surrounding tissue), a key factor in the promotion
of inflammation. Numerous studies have demonstrated that the
anti-histamine action of Flavay® is obtained through inhibiting
the activity of the enzyme histidine decarboxylase. Research
shows that Flavay® may lower the production of histamine
with as much as 86% inhibition of histidine decarboxylase.
In an Australian study conducted on two groups of soccer players
that had sustained injuries, those that consumed Flavay®
for ten days following their injuries experienced significantly
less swelling than those who did not and, in some of those taking
Flavay®, the swelling had completely disappeared. Other
research has demonstrated the ways in which Flavay® may
actually inhibit inflammation including double-blind studies
conducted in France which showed that Flavay® can reduce
postoperative inflammation.
Proven Safety of Flavay®
After more than 50 years of human use, no adverse effects have been observed.
Furthermore, intensive biological, toxicological, pharmacological and analytical
research was conducted for the purpose of registering it as a medicine in France
and other countries in Europe. In one study, daily doses of up to 35,000 mg
for six months were determined to cause no adverse effects. Flavay® was
also clinically tested, in particular for all sorts of symptoms related to venolymphatic
insufficiencies (strenghthening veins, improving circulation and reducing edema
and inflammations). The spin-off is a goldmine of data: The rigorous testing
to meet the standards required by the health ministries of France, Germany and
other European countries demonstrate that Flavay® is highly bioavailable,
nontoxic, nonallergenic, noncarcinogenic, nonmutagenic, will not cause birth
defects, and is completely safe.
Dr. Masquelier’s unequaled manufacturing process has been conducted
for half a century at the very same facilities in France, and under the
control of French Pharmaceutical inspection. These time-proven standards
serve as a reliable assurance of the quality, consistency, bioavailability
and safety of Flavay®.
Who can take Flavay®?
Everyone, from the very young to elderly. Flavay® has no known contraindications
(conditions under which it should not be used). Flavay® is completely safe
and nontoxic. In fact, clinical trials have been conducted in which pregnant
women (troubled by varicose veins and other circulatory problems in the
legs) safely used Flavay®.
Why Trust Flavay®
Consumers need to know that the marketplace is full of imitations, various
“extracts” and derivative forms of Dr. Masquelier’s scientifically
proven and patented complex. Unfortunately, many have even used Dr. Masquelier’s
name and research in unauthorized ways to promote illegitimate products.
Flavay® is the name you can trust for the precisely
defined active polyphenol complex patented and perfected by the inventor, Dr.
Jack Masquelier, validated by the French Ministry of Health and documented by
a library of research consisting of many patents and hundreds of scientific
papers, articles, doctorate theses, lectures and presentations. For quality,
consistency, bioavailablity and safety, consumers may rely upon Flavay®.
Flavay® Improves the Health
and Appearance of Skin
Flavay® is the amazing internal
cosmetic, improving the health and appearance of the skin from
the inside out: rebuilding collagen, improving circulation and
health in skin cells, and reducing inflammation.
Statements made herein have not been
evaluated by the Food and Drug Administration. These products are not intended
to diagnose, treat, cure or prevent any disease.
Masquelier, J. Plant extract
with a proanthocyanidins content as a therapeutic agent having
radical scavenging effect and use thereof. U.S. Patent No. 4,698,360,
1987.
Masquelier, J. A lifetime devoted to OPC and Pycnogenols. Alfa
Omega Editrice, Pub., 1996.
Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice,
Publishers, 1995.
Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats
Publishing, Inc., 1997.
Mindell, E., et al. Earl Mindell’s vitamin bible for the
21st century. Warner Books, Inc., 1999.
Passwater, R.A. The antioxidants: the nutrients that guard your
body. Keats Publishing, Inc., 1985.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants.
Keats Publishing, Inc., 1995.
Facino RM, et al. Free radical scavenging action and anti-enzyme
activities of procyanidines from Vitis vinifera. A mechanism for
their capillary protective action. Arzneimittelforschung, 44:
592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant
to the action of mammalian collagenase. Experientia, 37: 221-223,
1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres
procyanidoliques. Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides.
A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques
totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres flavonoliques.
Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action
des oligomeres procyanidoliques sur des cellules mesenchymateuses
en culture. Ii l’attachment des fibres elastiques aux cellules.
(Study of the effect of procyanidolic oligomers on mesenchymal
cells in culture. Ii attachment of elastic fibers to the cells.)
Pat Biol, (30)6:601-7, 1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular
and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin
[(2r,3s,+r)-(+)-3,3’, 4.4’, 5.7’-Hexahydroxyflavan]
dihydrate, and comparison of its heterocyclic ring conformation
in solution and the solid state. Journal of the Chemical Society;
Perkin Transactions I 1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free
radicals. Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins
b-1 and b-3 from azuki beans to peroxyl radicals. Agric Biol Chem,
54(10) 1990. pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different
procyanidins from grape seeds. Presented at a symposium, “Free
radicals in biotechnology and medicine.” Royal Society Of
Chemistry, London January 1990, pp. 79-80.
Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase
durch flavonoide und phenolderivate im vergleich nit deren 02
radikalfangereigenschaften” Arch Pharm, (Weinheim) 313 (1980)
pp. 330-337.
Lombard, J., et al. The brain wellness plan. Kensington Pub. Corp.,
1998.
Flesch M., et al., Effects of red and white wine on endothelium-dependent
vasorelaxation of rat aorta and human coronary arteries. Am J
Physiol 1998;275:1183-94.
Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM.
Isolation and characterization of endothelium-dependent vasorelaxing
compounds from grape seeds. J Agr & Food Chem In press.
Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation,
endothelium, and wine. BioFactors 1997;6:455-459.
Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey
RG. Endothelium-dependent vasorelaxation caused by various plant
extracts. J Cardiovasc Pharmacol 1995;26:90-95.
Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent
vasorelaxing activity of wine and other grape products. Amer J
Physiol 1993;265:H774-H778.
Lincoln, J., Hoyle, C.H.V., Burnstock, G., Nitric oxide in health
and disease. Cambridge University Press, 1997.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme
activities of procyanidines from vitis vinifera. A mechanism for
their capillary protective action. Arzneimittelforschung, 44:
592-601, 1994.
Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with
catechin becomes resistant to the action of mammalian collagenase.
Experientia, 37: 221-223, 1981.
Masquelier, J. Procyanidolic oligomers. J Parums Cosm Arom, 95:
89-97, 1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies
that binding of pycnogenols to elastin affects its rate of degradation
by elastases. Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985.
Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers
extracted from ‘vitus vinifera l.’ in the rat. European
Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1
pp. 15-30.
Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging
activity of proanthocyanidolic oligomers encapsulated in glycospheres:
an in vivo and in vitro study. Cosmetology Department & S
Biovectors, Ramonville St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i
converting enzyme by flavanolic compounds: in vitro and in vivo
studies. Planta Medica, May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex
Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-activite aniagoniste vis-a-vis des mediateurs
de l’inflamation. Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance capillaire,
spontanement ou artificiellement diminuee par l’action d’une
substance capillaro-toxique chez des personnes agees--action benefique
d’un agnet actif sur la micro-circulation: l’Endotelon.
Inform. Therapeut. 1980. pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude
d’un microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7,
1990.
Lagrue, G., Olivier-Martin, F., Grillot, A. “Etude des effets
des oligomeres du procyanidol sur las resistance capillaire dand
l’hypertension arterielle et certaines nephropathies.”
Sen. Hosp. Paris 18-25 Septembre, 1981.
Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur
peripherique, l’Endotelon. Actualite Therapeutique Gaz. Med.
de France (87)22:2919-24, 1980.
Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice
de fragilite capillaire dan une population specifique: les sujets
cirrhotiques. Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres
inferieurs par un microangioprotecteur l’Endotelon. Bordeaux
Med, 11:685-8, 1981.
Delacroix, P. Etude en double aveugle de l’Endotelon dans
l’insuffisance veineuse chronique. Therapeutique, la Revue
de Medicine, (27-28) Sept. 1981. pp. 1793-1802.
Thebaut, J.F, Thebaut, P., Vin, F. Etude de l’Endotelon dand
les manifestations fonctionnelles de l’insuffisance veineuse
peripherique-resultats d’une etude en double aveugle portant
sur 92 patients.” Gazette Medicale, (92)1, 1985. pp. 96-100.
Masquelier, J. Pycnogenols: recent advances in the therapeutical
activity of procyanidins. Supplement of Planta Medica, Journal
of Medicinal Plant Research and Journal of Natural Products, July
1980 pp. 243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury:
implications in atherosclerosis. Free Rad Path & Med, (4)1988
pp. 99-106.
Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.”
pp. 88-93.
Gazave, J.M. “Notions recentes sur les capillaires”
unpub. bulletin from the Laboratoire De Physiologie Patholigie
pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation
and atherothrombosis. Office International Vigne et du Vin, Nutrition
and Health Unit, Paris France; Drugs under Experimental and Clinical
Research (Switz.) 25/2-3 (125-131), 1999.
Blaszo, G. Gabor, M. Oedema-inhibiting effect of procyanidin.
Acta Physiologica Academiae Scientiarum Hungaricae, Tomus 56(2):235-240,
1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase.
Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie.
Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P “Une Etude Exemplaire Pour Un Phlebotrope: l’etude
EIVE.’ Unpub., pp. 77-83.
Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres
procyanidoliques dans la paroi des capillaires sanguins du poumon
decobaye. Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di Ferrante, N. “Collagen treated
with (+) -catechin becomes resistant to the action of mammalian
collagenase.” Laboratory of Connective Tissue Research, Dept.
of Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980.
Gendre, P., Laparra, J., Barraud, E. “Effect protecteur des
oligomeres procyanidoliques sur le lathyrisme experimental chez
le rat.” Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal
circulation. Study of the effect of procyanidolic oligomer (Endotelon).
Jn. Fr. Opthalmol, (11)5:453-460, 1988.
Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and
dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol
Fr, 88(2):173-4, 177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside
oligomers effects on retinal function in myopic subjects. Ann
Ott Clin Ocul, 114:85-93, 1988.
Saracco, J.B., Estachy, G.M. Etude d l’Endotelon en opthalmologie.
Gaz Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies.
Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr. Opthalmol,
11:453, 1988.
Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et O.P.C.
Bordeaux Medicale, (16)11. pp. 1467-74, 1978.
Soyeux, A. et al. Endotelon. Diabetic retinopathy and hemorheology.
Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. “Les oligomeres procyanidoliques dans le traitement
de la fragilite capillaire et de la retinopathie chez les diabetiques.
A propos de 26 cas.” Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques:
Endotelon, dans la retinopathie diabetique (a propos de 30 observations).
Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results
of a double-blind study versus placebo in 32 female patients.
Ann Chir Plast Esthet 29(4):393-5, 1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism
in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62,
1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels.
Angiologica, 9:355-374, 1972.
Havsteen, B. Flavonoids, a class of natural products of high pharmacological
potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer,
H.J. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger.,
1977.
Masquelier, J. Action protectrice du vin sur l’ulcere gastrique.
Resultats, p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by
flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985.
Packer, L., et al. The antioxidant miracle: your complete plan.
John Wiley & Sons, Inc., 1999.
Shaw, R. How [Australian] PycnoGenol [MASQUELIER’s®]
Helps Sports People.
Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums
Cosmet Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques
(Endotelon) dans le traitement des lymphoedemes post-therepeutiques
de members superieurs. Symposium Satellite, Congres International
d’Angiologie, Toulouse, France, 4-7 Oct. 1989.
Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine during
2 weeks of intense training. Abstract submitted to national meeting
of the Amer College of Sports Medicine, June 1998.
Monteleone, P., Maj, M., Beinat, L., Natale, M., Kemali, D. Blunting
by chronic phosphatidylserine administration of the stress-induced
activation of the hypothalamo-pituitary-adrenal axis in healthy
men. Eur J Clin Pharm 43: 385–388, 1992.
Fahey, T.D., et al. The hormonal and perceptive effects of phosphatidylserine
administration during two weeks of resistive exercise-induced
overtraining. Bio of Sport 15(3):135-44, 1998.
Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres
procyanidoliques sur le cobaye carence en vitamin c. Tavaux Originaux,
University of Bordeaux, 1976.
Masquelier, J. Action comparee de divers facteurs vitaminiques
p sur l’oxydation de l’acide ascorbique par les ions
cuivriques. Bull. de la Societe de Chimie Biologique XXXIII (3-4)
1951. pp. 302-304.
Masquelier, J. Action comparee de divers facteurs vitaminiques
p sur l’acide ascorbique-oxydase. Bull. de la Societe de
Chimie Biologique XXXIII (3,4) 1951. pp.304-306
Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G.,
Mishioka, I. “Inhibitory effects of tannins on hyaluronidase
activation and on the degranulation from rat mesentery mast cells.”
Chem. Pharm. Bull. 33(11)1985. 5079-5082.
Reiman, H.J., Lorenz, M., Fischer, R., Frolich, H., Meyer, J.
“Histamine and acute haemorrhagic lesions in rat gastric
mucosa: prevention of stress ulcer formulation by (+)-catechin,
an inhibitor of specific histidine decarboxylase in vitro.”
Dirkhauser Verlag,Vol. 7/1, 1977.
Pariente, J.J. Parientl-Amsellem, J. “Les oedemes post-traumatoqies
chez le sportif: essai controle de l’Endothelon.” Actualite
Therapeutique 90(3) 2/11 1983 pp. 231-235.
Masquelier, J., et al. “Flavonoids et Pycnogenols” Int
J Vit Nut Res, (49)3:307-311, 1979.
Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem.
Toxicol. 25(2):135-9, 1987.
Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica
Report, 1971.
Laparra, J., et al., Acta Therapeutica, 4:233, 1978.
Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow
cells of the mouse with Pycnogenol. Cytotest Cell Research GmbH
& Co., projects 143010 & 143021; Feb. 1989.
Acute and chronic toxicity tests. International Bio-Research,
Inc., Hanover, Germany, 1967-1971.
Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content
in vegetable extracts to be used in the preparation of medicines.
Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.
